logo-loader
RNS
Feedback PLC

Feedback PLC - Statement re share price

RNS Number : 0086O
Feedback PLC
27 September 2019
 

Feedback plc

Statement re share price

Cambridge, 27 September 2019Feedback plc (AIM: FDBK, "Feedback" or the "Company") notes the movement in the share price today.  The Company notes the announcement earlier today by IQ-AI Ltd that Imaging Biometrics, IQ-AI's Milwaukee based subsidiary, today received notification that the FDA has cleared StoneChecker Software for marketing in the USA ("the FDA Clearance").  Stonechecker is a licensee of Feedback's TexRAD® software and the Directors believe that the Stonechecker Software uses TexRAD®. However, the Company is currently not able to evaluate what level of income, if any, will accrue as a result of the FDA Clearance.  In addition, the FDA Clearance does not confer FDA clearance for TexRAD® and the Directors are now evaluating the implications of this as part of their ongoing strategic review.

A further announcement will be made in due course.

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO 

 

+44 (0)1954 718072

IR@fbk.com

Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai 

 

+44 (0)20 3328 5656

Peterhouse Capital Limited (Joint Broker)

Lucy Williams / Duncan Vasey 

 

+44 (0)20 7469 0936

Stanford Capital Partners Limited (Joint Broker)

Patrick Claridge / John Howes

 

Instinctif Partners

Rozi Morris/ Deborah Bell/ Phillip Marriage

+44 20 3815 8880

 

 

+44 (0)20 7457 2020

feedbackplc@instinctif.com

 

Notes to editors

About Feedback plc

Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer. Feedback Medical works with customers globally from headquarters in the internationally renowned scientific hub of Cambridge, UK. Its proprietary technologies are TexRAD®, the quantitative texture analysis tool and Cadran, a picture archiving communication system (PACS). The Company has recently announced the launch of its new messaging and image transfer product Bleepa™. For more information, see www.fbk.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
SPMBXGDCISDBGCR
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read